CASI Pharmaceuticals (CASIF) Cash & Equivalents (2021 - 2025)

CASI Pharmaceuticals has reported Cash & Equivalents for 5 years, with the latest figure at $5.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 58.18% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (down 58.18% YoY), and the FY2025 full-year result was $5.6 million, down 58.18% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $5.6 million, up from $4.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $47.1 million in Q4 2022, with the low at $9533.0 in Q2 2024.
• Historically, Cash & Equivalents has averaged $13.5 million across 5 years, with a median of $9.5 million in 2024.
• The largest YoY upside for Cash & Equivalents was 70601.77% in 2025 against a maximum downside of 99.91% in 2025.
• CASI Pharmaceuticals' Cash & Equivalents stood at $38.7 million in 2021, then gained by 21.72% to $47.1 million in 2022, then tumbled by 63.74% to $17.1 million in 2023, then declined by 21.16% to $13.5 million in 2024, then plunged by 58.18% to $5.6 million in 2025.
• The last three Cash & Equivalents figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.